• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.32% Nasdaq Down0.01%

    More On QPT.V

    Quotes

    Charts

    News & Info

    Company

    Analyst Coverage

    • Analyst Opinion
    • Analyst Estimates

    Ownership

    • Major Holders
    • Insider Transactions
    • Insider Roster

    Financials


    Quest PharmaTech, Inc. (QPT.V)

    -TSXV
    0.05 0.00(0.00%) Jul 31, 1:14PM EDT
    Add to Portfolio
    ProfileGet Profile for:
    Quest PharmaTech, Inc.
    8123 Roper Road NW
    Edmonton, AB T6E 6S4
    Canada - Map
    Phone: 780-448-1400
    Fax: 780-416-0324
    Website: http://www.questpharmatech.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:N/A

    Business Summary 

    Quest PharmaTech Inc., a clinical stage biotechnology company, engages in the development and commercialization of oncology products. It develops a portfolio of product candidates for the treatment of cancer by combining immunotherapeutic antibodies with chemotherapy, immune-adjuvants, and photodynamic therapy. The company's lead product candidate, Oregovomab, an immunotherapeutic product for the treatment of ovarian cancer and is under a multi-center Phase IIb clinical trials in Italy and the United States. The company also develops MUC1 program that has completed phase I clinical trials for the treatment of cancer tumors; and SL052, a photosensitizer product, which is under phase I clinical trials and is intended for the treatment of prostate cancer. Quest PharmaTech Inc. has a strategic relationship with with AD Biotech Co., Ltd. The company is headquartered in Edmonton, Canada.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Quest PharmaTech, Inc.

    Key Executives 
     PayExercised
    Dr. Ragupathy Madiyalakan Ph.D.,
    Chief Exec. Officer, Director, Ex-Officio Member of Compensation Committee, Ex-Officio Member of Audit Committee and Ex-Officio Member of Corp. Governance Committee
    150.00K0.00
    Mr. Pierre Vermette C.A.,
    Chief Financial Officer
    100.00K0.00
    Mr. Thomas Woo M.Sc.,
    VP of Product Devel.
    126.00K0.00
    Mr. Roger Andrews ,
    Head of Investor Relations & Corp. Communications
    N/AN/A
    Mr. Douglas C. Bachman , 61
    VP of Corp. Devel.
    N/AN/A
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in CAD.